The economic impact of parallel imports of pharmaceuticals – an assessment of savings in denmark in 2021
The economic impact of parallel imports of pharmaceuticals – an assessment of savings in denmark in 2021
Original title: Effekten af parallel-importeret medicin – en opgørelse af besparelsen i Danmark i 2021
The practice of parallel imports of pharmaceuticals has taken place in Denmark and the rest of the EU since the 1970s. In 2021, parallel imports accounted for 16% of turnover in the Danish market for medicinal products. Parallel-imported pharmaceuticals are original pharmaceuticals imported from another EU/EEA country where they are cheaper than in Denmark. Hence, they are the same medicinal products as those sold by original manufacturers in Denmark.
The main conclusions of our study
The total savings from parallel imports of pharmaceuticals in Denmark amounted to DKK 740 million in 2021
Total savings correspond to 3% of the total expenditure on pharmaceuticals in Denmark, or an average saving on parallel-imported products of 16%
Total savings have increased by DKK 130 million, corresponding to 21%, between 2018 and 2021
The study is commissioned by the Danish Association of Parallel Importers of Pharmaceuticals (Foreningen for Parallelimportører af Medicin).
contact us
Click below to read more about our Healthcare & Life Sciences service.
Related work
The Danish Association of Parallel Importers of Pharmaceuticals
The economic impact of parallel imports of pharmaceuticals
The Suppliers of Parallel Imported Medicines in Finland
Savings from parallel import of pharmaceuticals in Finland 2016-2020